Efficacy of periprosthetic erythromycin delivery for wear debris-induced inflammation and osteolysis

Inflammation Research

Volumn 59, Issue 12, 2010, Pages 1091-1097

  Ren, Weiping ^a,c   Zhang, Renwen ^b   Hawkins, Monica ^b   Shi, Tong ^c   Markel, David C ^a  

^a PROVIDENCE HOSPITAL   (United States)

^b STRYKER ORTHOPAEDICS   (United States)

^c Wayne State University   (United States)

Author keywords

Animal model; Erythromycin; Osteolysis; Wear debris

Indexed keywords

ERYTHROMYCIN; PENICILLIN G; STREPTOMYCIN; TITANIUM; ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; FEMALE; HISTOPATHOLOGY; LOADING TEST; MECHANICAL STRESS; NONHUMAN; OSTEOLYSIS; PROSTHESIS LOOSENING; RAT; REOPERATION; SOFT TISSUE INFLAMMATION; TRABECULAR BONE;

ANIMALS; ANTI-BACTERIAL AGENTS; COATED MATERIALS, BIOCOMPATIBLE; ERYTHROMYCIN; HUMANS; IMPLANTS, EXPERIMENTAL; INFLAMMATION; OSTEOLYSIS; POLYETHYLENES; PROSTHESIS FAILURE; RATS; RATS, SPRAGUE-DAWLEY; TIBIA; TITANIUM;

EID: 78651278472     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-010-0229-x     Document Type: Article

References (41)

1. Berry DJ, Harmsen WS, Cabanela ME, Morrey BF. Twentyfive-year survivorship of two thousand consecutive primary charnley total hip replacements: factors affecting survivorship of acetabular and femoral components. J Bone Joint Surg Am. 2002;84:171-7.
2. Keener JD, Callaghan JJ, Goetz DD, et al. Twenty-five-year results after Charnley total hip arthroplasty in patients less than fifty years old: a concise follow-up of a previous report. J Bone Joint Surg Am. 2003;85-A: 1066-72.
3. Fender D, Harper WM, Gregg PJ. Outcome of Charnley total hip replacement across a single health region in England: the results at five years from a regional hip register [see comments]. J Bone Joint Surg Br. 1999;81:577-81.
4. Ingham E, Fisher J. Biological reactions to wear debris in total joint replacement. Proc Inst Mech Eng [H]. 2000;214:21-37.
5. Greenfield EM, Bi Y, Ragab AA, et al. The role of osteoclast differentiation in aseptic loosening. J Orthop Res. 2002;20:1-8.
6. Merkel KD, Erdmann JM, McHugh KP, et al. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol. 1999;154:203-10.
7. Stea S, Visentin M, Granchi D, et al. Wear debris and cytokine production in the interface membrane of loosened prostheses. J Biomater Sci Polym Ed. 1999;10:247-57.
8. Maloney WJ, Smith RL, Schmalzried TP, et al. Isolation and characterization of wear particles generated in patients who have had failure of a hip arthroplasty without cement. J Bone Joint Surg Am. 1995;77:1301-10.
9. Sethi RK, Neavyn MJ, Rubash HE, Shanbhag AS. Macrophage response to cross-linked and conventional UHMWPE. Biomaterials. 2003;24:2561-73.
10. Wooley PH, Schwarz EM. Aseptic loosening. Gene Ther. 2004;11:402-7.
11. Schwarz EM. What potential biologic treatments are available for osteolysis? J Am Acad Orthop Surg. 2008;16(Suppl 1): S72-5.
12. Pollice PF, Rosier RN, Looney RJ, et al. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes: a potential treatment for aseptic loosening of total joint components. J Bone Joint Surg Am. 2001;83-A: 1057-61.
13. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM. Efficacy of etanercept for wear debris-induced osteolysis. J Bone Miner Res. 2001;16:338-47.
14. Yatsunami J, Hayashi S. Fourteen-membered ring macrolides as anti-angiogenic compounds. Anticancer Res. 2001;21:4253-8.
15. Cervin A. The anti-inflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitis. Acta Otolaryngol. 2001;121:83-92.
16. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents. 2008;31:12-20.
17. Nagai H, Shishido H, Yoneda R, et al. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration. 1991;58:145-9.
18. Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. Thorax. 1997;52:915-8.
19. Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829-32.
20. Sakito O, Kadota J, Kohno S, et al. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration. 1996;63:42-8.
21. Dette GA, Knothe H, Kellner HM. Whole body tissue distribution of [14C]-erythromycin in the guinea pig. an autoradiographic study. Arzneimittelforschung. 1987;37:524-7.
22. Cuffini AM, Tullio V, Cimino F, Carlone NA. Comparative effects of roxithromycin and erythromycin on cellular immune functions in vitro. 1. Uptake of 3H-macrolides by human macrophages. Microbios. 1989;57:167-78.
23. Ren WP, Li XY, Chen BD, Wooley PH. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NFkB activity. J Orthop Res. 2004;22:21-9.
24. Ren WP, Bin W, Mayton L, Wooley PH. Erythromycin (EM) inhibits wear debris-induced inflammatory osteolysis in a murine model. J Orthop Res. 2006;24:280-90.
25. Ren W, Blasier R, Peng X, et al. Effect of oral erythromycin therapy in patients with aseptic loosening of joint prostheses. Bone. 2009;44:671-7.
26. Stephenson PK, Freeman MA, Revell PA, et al. The effect of hydroxyapatite coating on ingrowth of bone into cavities in an implant. J Arthroplasty. 1991;6:51-8.
27. Karabatsos B, Myerthall SL, Fornasier VL, et al. Osseointegration of hydroxyapatite porous-coated femoral implants in a canine model. Clin Orthop Relat Res. 2001;392:442-9.
28. Hansson U, Ryd L, Toksvig-Larsen S. A randomised RSA study of Peri-Apatite HA coating of a total knee prosthesis. Knee. 2008;15:211-6.
29. Zhang R, An Y, Toth CA, et al. Osteogenic protein-1 enhances osseointegration of titanium implants coated with peri-apatite in rabbit femoral defect. J Biomed Mater Res B Appl Biomater. 2004;71:408-13.
30. Zhang R, Xu D, Landeryou T, et al. Ectopic bone formation using osteogenic protein-1 carried by a solution precipitated hydroxyapatite. J Biomed Mater Res A. 2004;71:412-8.
31. Wooley PH, Morren R, Andary J, et al. Inflammatory responses to orthopaedic biomaterials in the murine air pouch. Biomaterials. 2002;23:517-26.
32. Ren WP, Yang S, Wooley PH. A novel murine model of orthopaedic wear debris-associated osteolysis. Scand J Rheumatol. 2004;33:349-57.
33. Allen M, Brett F, Millett P, Rushton N. The effects of particulate polyethylene at a weight-bearing bone-implant interface A study in rats. J Bone Joint Surg Br. 1996;78:32-7.
34. Morawietz L, Classen RA, Schroder JH, et al. Proposal for a histopathological consensus classification of the periprosthetic interface membrane. J Clin Pathol. 2006;59:591-7.
35. al Saffar N, Revell PA. Pathology of the bone-implant interfaces. J Long Term Eff Med Implants. 1999;9:319-47.
36. Jones LC, Frondoza C, Hungerford DS. Immunohistochemical evaluation of interface membranes from failed cemented and uncemented acetabular components. J Biomed Mater Res. 1999;48:889-98.
37. Yang SY, Ren W, Park Y, et al. Diverse cellular and apoptotic responses to variant shapes of UHMWPE particles in a murine model of inflammation. Biomaterials. 2002;23:3535-43.
38. Ginebra MP, Traykova T, Planell JA. Calcium phosphate cements as bone drug delivery systems: a review. J Control Release. 2006;113:102-10.
39. Naber CK. Future strategies for treating Staphylococcus aureus bloodstream infections. Clin Microbiol Infect. 2008;14(Suppl 2):26-34.
40. Stigter M, Bezemer J, De GK, Layrolle P. Incorporation of different antibiotics into carbonated hydroxyapatite coatings on titanium implants, release and antibiotic efficacy. J Control Release. 2004;99:127-37.
41. Stigter M, De GK, Layrolle P. Incorporation of tobramycin into biomimetic hydroxyapatite coating on titanium. Biomaterials. 2002;23:4143-53.